) The principal objective of the G e isinger Clinical Oncology Program is to enroll maximal numbers of patients/subjects onto NCI-approved cancer prevention, cancer control and cancer treatment protocols, bringing research-quality care to a large rural population of Pennsylvania. The Geisinger Health System serves more than 2.3 million Pennsylvanians across 31 primarily rural counties in the central and northeastern parts of the State. The CCOP is based in a 550 physician primary and multispecialty group practice in 50 sites anchored by a 568 bed tertiary care medical center in Danville: The Geisinger Medical Center. Satellite facilities will participate in the Wilkes-Barre and State College areas. The health system operates a staff model, not-for-profit HMO with over 200,000 members that works cooperatively with the CCOP to promote cancer prevention trials. Among Geisinger CCOP's advantages are a stable CCOP staff with successful performance over the 14 year history of the NCI CCOP program. There is a large network of primary care practices, linked by computerized record systems and a large cancer patient population. A rarity in the era of managed care is a strong continuing institutional commitment to clinical research trials in cancer, and a willingness of both the Center and the HMO to fund important prevention and treatment trials, not as a marketing tool, but as part of it's primary mission. The ease of performing clinical trails is enhanced by an excellent unit record system, extensive high-quality tumor registry and interlocking computerized systems for laboratory, pathology, radiology, demographic and appointments data. This proposal retains the NCCTG as Geisinger's primary research base, includes ECOG as a secondary base, CCG as a special childrens base, and proposes a new additional base, the GOG to provide a vehicle for recruiting more women onto treatment, prevention and control studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035448-15
Application #
2662586
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J3))
Project Start
1998-07-01
Project End
2003-05-31
Budget Start
1998-07-01
Budget End
1999-05-31
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Geisinger Medical Center
Department
Type
DUNS #
City
Danville
State
PA
Country
United States
Zip Code
17822
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Patel, Krishna; Foster, Nathan R; Farrell, Ann et al. (2013) Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 28:770-6
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 115 publications